Loading...
Treatment of Chronic HCV Infection with Direct Acting Antivirals
Зохиогч
Bekhbold Dashtseren
Zulkhuu Genden
Odgerel Oidovsambuu
Anir Enkhbat
Ganbolor Jargalsaikhan
Sumiya Byambabaatar
Myammarsuren Shagdarsuren
Altankhuu Murdorj
Naranbaatar Dashdorj
Naranjargal Dashdorj
Он
2021 оны есдүгээр сарын 21
Төрөл
journal article
Хэвлэгч
Mongolian National University of Medical Sciences
Journal
Central Asian Journal of Medical Sciences
Volume
7
Issue
3
Start Page
222
End Page
230
ISSN
2413-8681
2414-9772
Хураангуй
Objectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs). Methods: Based on the Liver Center database, we studied the treatment effect of Sofosbuvir 400 mg/Ledipasvir 90 mg in 1109 patients with chronic hepatitis C virus infection during the time period from December 2015 to December, 2018. Results: In patients treated with Sofosbuvir/Ledipasvir, the sustained viral load (SVR12) was 97.9% (1086/1109) 12 weeks after the treatment. The SVR12 was 99.2% (845/851) in HCV-infected non-cirrhotic patients, 93.4% (241/258) in patients with cirrhosis, and 80% (8/10) among patients treated for liver cancer. The SVR12 (19/25) was lowered to 76% at 12 weeks of treatment with Sofosbuvir 400 mg/ Daclatasvir 60 mg in DAA-failure patients 23/1109 (2.07%). Conclusions: SVR12 rates in non-cirrhotic and cirrhotic patients were 99.2% and 93.4%, respectively, while it was 80% in liver cancer patients after DAA treatment. As for patients with viral relapse, 76% of them were successfully retreated with second-line DAA treatment. During the DAA treatment, only 17.6% of all patients had some adverse effects related to DAA treatment, thus, DAA treatment is suitable for Mongolian patients and has less adverse effects.